Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Hereditary Angioedema Therapeutic Market by Route of Administration (Intravenous, Subcutaneous, Oral) and by Treatment (Short Term Prophylaxis, Long Term Prophylaxis): Global Opportunity Analysis and Industry Forecast, 2023-2032

A10476

Pages: NA

Charts: NA

Tables: NA

Hereditary Angioedema (HAE) is an inherited condition characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous or submucosal swelling without the presence of urticarial lesions due to C1 protein inhibition. C1 inhibition leads to accumulation of Bradikynin, which leads to fluid leakage. Lymphatic or blood flow, constant accumulation of liquids outside of the veins, brings about swelling of tissues in the feet, arms, intestinal tract, airway, or face. Hereditary Angioedema might be obtained or acquired; it is more common in youngsters.  Multiple areas of the body can be involved including hands, feet, intestinal wall, genitalia, face, tongue, or larynx.1 Swelling of the pharynx or larynx can be life–threatening due to asphyxia. Hereditary Angioedema is a burdensome disease that can lead to debilitating and dangerous Angioedema episodes associated with significant costs for individuals and society. The burden of treatment must be addressed regarding medication administration difficulties, treatment complications, and adverse side effects.

Impact of Covid-19 on market:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine, have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Market Scenario Analysis- Drivers, Opportunities, Risks and Challenge Factors:

The increase in awareness due to government initiatives, improved management, and better outcomes and rise in demand for preventive care are few of the market driving factors. Shift toward gene therapy is one of the recent opportunities available in the Hereditary Angioedema Therapeutic market. Also, the government recommendation for drugs recently available is also rising opportunities. Delay in effective treatment due to appendicitis and other such allergies acts as a market restraint factor.

Hereditary Angioedema Therapeutic market growth is hampered due to high cost of drugs as well. The risk of thrombosis associated with C1-inhibitor (C1-INH), worsening attacks with fresh frozen plasma (FFP) and carcinoma secondary to androgens (mainly danazol) are few of the market restraint factors. To develop better medicines with no side effects is a challenge in the market.

Rise in demand of Subcutaneous Injection:

Subcutaneous injections are highly effective in administering medications such as insulin, morphine, diacetylmorphine and goserelin. Rise in demand of easy-usage for patients is estimated to increase demand of subcutaneous injections as a mode of drug administration.

New Therapies & Innovations Contributing to Hereditary Angioedema Treatment Market Growth:

The R&D segment is estimated to drive the Hereditary Angioedema Therapeutic market growth rapid increase in the development of drugs for hereditary angioedema treatment. In August 2018, The US Food and Drug Administration (FDA) approved lanadelumab (Takhzyro, Shire). It is the first monoclonal antibody to help prevent attacks of hereditary angioedema (HAE) in patients. In June 2017, CSL Behring developed drug namely Haegarda® (C1 Esterase Inhibitor) was approved by FDA. It is a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients.

Key Benefits of the Report:

  • This study presents the analytical depiction of the global Hereditary Angioedema Therapeutic market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Hereditary Angioedema Therapeutic market share.
  • The current market is quantitatively analyzed to highlight the global Hereditary Angioedema Therapeutic market growth scenario.
  • The report provides a detailed global Hereditary Angioedema Therapeutic market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Hereditary Angioedema Therapeutic Market research report:

  • Which are the leading market players active in the Hereditary Angioedema Therapeutic market?
  • What are the driving factors, challenges, and opportunities in the Hereditary Angioedema Therapeutic market?
  • What are the different market segments in this Hereditary Angioedema Therapeutic market?
  • What are the projections for the future that would help in taking further strategic steps?

 Key Market Segments

  • By Route of Administration
    • Intravenous
    • Subcutaneous
    • Oral
  • By Treatment
    • Short Term Prophylaxis
    • Long Term Prophylaxis
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Pharming Healthcare, Inc.,
  • CSL Behring,
  • BioCryst Pharmaceuticals, Inc.,
  • Adverum Biotechnologies, Inc.
  • KalVista Pharmaceuticals, Inc.,
  • Takeda Pharmaceutical Company Limited,
  • Takeda Pharmaceutical Company,
  • Shire Plc.
  • Ionis Pharmaceuticals,
  • Attune Pharmaceuticals, Inc.,

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Route Of Administration

    • 4.2. Intravenous

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Subcutaneous

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Oral

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET, BY TREATMENT

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Treatment

    • 5.2. Short Term Prophylaxis

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Long Term Prophylaxis

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Route Of Administration

      • 6.2.3. Market Size and Forecast, By Treatment

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Hereditary Angioedema Therapeutic Market

        • 6.2.5.1. Market Size and Forecast, By Route Of Administration
        • 6.2.5.2. Market Size and Forecast, By Treatment

      • 6.2.6. Canada Hereditary Angioedema Therapeutic Market

        • 6.2.6.1. Market Size and Forecast, By Route Of Administration
        • 6.2.6.2. Market Size and Forecast, By Treatment

      • 6.2.7. Mexico Hereditary Angioedema Therapeutic Market

        • 6.2.7.1. Market Size and Forecast, By Route Of Administration
        • 6.2.7.2. Market Size and Forecast, By Treatment

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Route Of Administration

      • 6.3.3. Market Size and Forecast, By Treatment

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Hereditary Angioedema Therapeutic Market

        • 6.3.5.1. Market Size and Forecast, By Route Of Administration
        • 6.3.5.2. Market Size and Forecast, By Treatment

      • 6.3.6. Germany Hereditary Angioedema Therapeutic Market

        • 6.3.6.1. Market Size and Forecast, By Route Of Administration
        • 6.3.6.2. Market Size and Forecast, By Treatment

      • 6.3.7. Italy Hereditary Angioedema Therapeutic Market

        • 6.3.7.1. Market Size and Forecast, By Route Of Administration
        • 6.3.7.2. Market Size and Forecast, By Treatment

      • 6.3.8. Spain Hereditary Angioedema Therapeutic Market

        • 6.3.8.1. Market Size and Forecast, By Route Of Administration
        • 6.3.8.2. Market Size and Forecast, By Treatment

      • 6.3.9. UK Hereditary Angioedema Therapeutic Market

        • 6.3.9.1. Market Size and Forecast, By Route Of Administration
        • 6.3.9.2. Market Size and Forecast, By Treatment

      • 6.3.10. Russia Hereditary Angioedema Therapeutic Market

        • 6.3.10.1. Market Size and Forecast, By Route Of Administration
        • 6.3.10.2. Market Size and Forecast, By Treatment

      • 6.3.11. Rest Of Europe Hereditary Angioedema Therapeutic Market

        • 6.3.11.1. Market Size and Forecast, By Route Of Administration
        • 6.3.11.2. Market Size and Forecast, By Treatment

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Route Of Administration

      • 6.4.3. Market Size and Forecast, By Treatment

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Hereditary Angioedema Therapeutic Market

        • 6.4.5.1. Market Size and Forecast, By Route Of Administration
        • 6.4.5.2. Market Size and Forecast, By Treatment

      • 6.4.6. Japan Hereditary Angioedema Therapeutic Market

        • 6.4.6.1. Market Size and Forecast, By Route Of Administration
        • 6.4.6.2. Market Size and Forecast, By Treatment

      • 6.4.7. India Hereditary Angioedema Therapeutic Market

        • 6.4.7.1. Market Size and Forecast, By Route Of Administration
        • 6.4.7.2. Market Size and Forecast, By Treatment

      • 6.4.8. South Korea Hereditary Angioedema Therapeutic Market

        • 6.4.8.1. Market Size and Forecast, By Route Of Administration
        • 6.4.8.2. Market Size and Forecast, By Treatment

      • 6.4.9. Australia Hereditary Angioedema Therapeutic Market

        • 6.4.9.1. Market Size and Forecast, By Route Of Administration
        • 6.4.9.2. Market Size and Forecast, By Treatment

      • 6.4.10. Thailand Hereditary Angioedema Therapeutic Market

        • 6.4.10.1. Market Size and Forecast, By Route Of Administration
        • 6.4.10.2. Market Size and Forecast, By Treatment

      • 6.4.11. Malaysia Hereditary Angioedema Therapeutic Market

        • 6.4.11.1. Market Size and Forecast, By Route Of Administration
        • 6.4.11.2. Market Size and Forecast, By Treatment

      • 6.4.12. Indonesia Hereditary Angioedema Therapeutic Market

        • 6.4.12.1. Market Size and Forecast, By Route Of Administration
        • 6.4.12.2. Market Size and Forecast, By Treatment

      • 6.4.13. Rest of Asia Pacific Hereditary Angioedema Therapeutic Market

        • 6.4.13.1. Market Size and Forecast, By Route Of Administration
        • 6.4.13.2. Market Size and Forecast, By Treatment

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Route Of Administration

      • 6.5.3. Market Size and Forecast, By Treatment

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Hereditary Angioedema Therapeutic Market

        • 6.5.5.1. Market Size and Forecast, By Route Of Administration
        • 6.5.5.2. Market Size and Forecast, By Treatment

      • 6.5.6. South Africa Hereditary Angioedema Therapeutic Market

        • 6.5.6.1. Market Size and Forecast, By Route Of Administration
        • 6.5.6.2. Market Size and Forecast, By Treatment

      • 6.5.7. Saudi Arabia Hereditary Angioedema Therapeutic Market

        • 6.5.7.1. Market Size and Forecast, By Route Of Administration
        • 6.5.7.2. Market Size and Forecast, By Treatment

      • 6.5.8. UAE Hereditary Angioedema Therapeutic Market

        • 6.5.8.1. Market Size and Forecast, By Route Of Administration
        • 6.5.8.2. Market Size and Forecast, By Treatment

      • 6.5.9. Argentina Hereditary Angioedema Therapeutic Market

        • 6.5.9.1. Market Size and Forecast, By Route Of Administration
        • 6.5.9.2. Market Size and Forecast, By Treatment

      • 6.5.10. Rest of LAMEA Hereditary Angioedema Therapeutic Market

        • 6.5.10.1. Market Size and Forecast, By Route Of Administration
        • 6.5.10.2. Market Size and Forecast, By Treatment

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. CSL Behring,

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Takeda Pharmaceutical Company Limited,

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Takeda Pharmaceutical Company,

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Pharming Healthcare, Inc.,

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. BioCryst Pharmaceuticals, Inc.,

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Attune Pharmaceuticals, Inc.,

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Ionis Pharmaceuticals,

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. KalVista Pharmaceuticals, Inc.,

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Adverum Biotechnologies, Inc.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Shire Plc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET FOR INTRAVENOUS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET FOR SUBCUTANEOUS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET FOR ORAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET FOR SHORT TERM PROPHYLAXIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET FOR LONG TERM PROPHYLAXIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 12. U.S. HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 13. U.S. HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 14. CANADA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 15. CANADA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 16. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 17. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 18. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 21. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 22. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 23. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 24. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 25. ITALY HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 26. ITALY HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 27. SPAIN HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 28. SPAIN HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 29. UK HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 30. UK HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 31. RUSSIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 32. RUSSIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 33. REST OF EUROPE HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 34. REST OF EUROPE HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 35. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 38. CHINA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 39. CHINA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 40. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 41. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 42. INDIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 43. INDIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 44. SOUTH KOREA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 45. SOUTH KOREA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 46. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 47. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 48. THAILAND HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 49. THAILAND HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 50. MALAYSIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 51. MALAYSIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 52. INDONESIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 53. INDONESIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 56. LAMEA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 59. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 60. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 61. SOUTH AFRICA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH AFRICA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 63. SAUDI ARABIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 64. SAUDI ARABIA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 65. UAE HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 66. UAE HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 67. ARGENTINA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 68. ARGENTINA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 69. REST OF LAMEA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 70. REST OF LAMEA HEREDITARY ANGIOEDEMA THERAPEUTIC, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 71. CSL BEHRING,: KEY EXECUTIVES
  • TABLE 72. CSL BEHRING,: COMPANY SNAPSHOT
  • TABLE 73. CSL BEHRING,: OPERATING SEGMENTS
  • TABLE 74. CSL BEHRING,: PRODUCT PORTFOLIO
  • TABLE 75. CSL BEHRING,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 76. TAKEDA PHARMACEUTICAL COMPANY LIMITED,: KEY EXECUTIVES
  • TABLE 77. TAKEDA PHARMACEUTICAL COMPANY LIMITED,: COMPANY SNAPSHOT
  • TABLE 78. TAKEDA PHARMACEUTICAL COMPANY LIMITED,: OPERATING SEGMENTS
  • TABLE 79. TAKEDA PHARMACEUTICAL COMPANY LIMITED,: PRODUCT PORTFOLIO
  • TABLE 80. TAKEDA PHARMACEUTICAL COMPANY LIMITED,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. TAKEDA PHARMACEUTICAL COMPANY,: KEY EXECUTIVES
  • TABLE 82. TAKEDA PHARMACEUTICAL COMPANY,: COMPANY SNAPSHOT
  • TABLE 83. TAKEDA PHARMACEUTICAL COMPANY,: OPERATING SEGMENTS
  • TABLE 84. TAKEDA PHARMACEUTICAL COMPANY,: PRODUCT PORTFOLIO
  • TABLE 85. TAKEDA PHARMACEUTICAL COMPANY,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. PHARMING HEALTHCARE, INC.,: KEY EXECUTIVES
  • TABLE 87. PHARMING HEALTHCARE, INC.,: COMPANY SNAPSHOT
  • TABLE 88. PHARMING HEALTHCARE, INC.,: OPERATING SEGMENTS
  • TABLE 89. PHARMING HEALTHCARE, INC.,: PRODUCT PORTFOLIO
  • TABLE 90. PHARMING HEALTHCARE, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. BIOCRYST PHARMACEUTICALS, INC.,: KEY EXECUTIVES
  • TABLE 92. BIOCRYST PHARMACEUTICALS, INC.,: COMPANY SNAPSHOT
  • TABLE 93. BIOCRYST PHARMACEUTICALS, INC.,: OPERATING SEGMENTS
  • TABLE 94. BIOCRYST PHARMACEUTICALS, INC.,: PRODUCT PORTFOLIO
  • TABLE 95. BIOCRYST PHARMACEUTICALS, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. ATTUNE PHARMACEUTICALS, INC.,: KEY EXECUTIVES
  • TABLE 97. ATTUNE PHARMACEUTICALS, INC.,: COMPANY SNAPSHOT
  • TABLE 98. ATTUNE PHARMACEUTICALS, INC.,: OPERATING SEGMENTS
  • TABLE 99. ATTUNE PHARMACEUTICALS, INC.,: PRODUCT PORTFOLIO
  • TABLE 100. ATTUNE PHARMACEUTICALS, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. IONIS PHARMACEUTICALS,: KEY EXECUTIVES
  • TABLE 102. IONIS PHARMACEUTICALS,: COMPANY SNAPSHOT
  • TABLE 103. IONIS PHARMACEUTICALS,: OPERATING SEGMENTS
  • TABLE 104. IONIS PHARMACEUTICALS,: PRODUCT PORTFOLIO
  • TABLE 105. IONIS PHARMACEUTICALS,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. KALVISTA PHARMACEUTICALS, INC.,: KEY EXECUTIVES
  • TABLE 107. KALVISTA PHARMACEUTICALS, INC.,: COMPANY SNAPSHOT
  • TABLE 108. KALVISTA PHARMACEUTICALS, INC.,: OPERATING SEGMENTS
  • TABLE 109. KALVISTA PHARMACEUTICALS, INC.,: PRODUCT PORTFOLIO
  • TABLE 110. KALVISTA PHARMACEUTICALS, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. ADVERUM BIOTECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 112. ADVERUM BIOTECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 113. ADVERUM BIOTECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 114. ADVERUM BIOTECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 115. ADVERUM BIOTECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. SHIRE PLC.: KEY EXECUTIVES
  • TABLE 117. SHIRE PLC.: COMPANY SNAPSHOT
  • TABLE 118. SHIRE PLC.: OPERATING SEGMENTS
  • TABLE 119. SHIRE PLC.: PRODUCT PORTFOLIO
  • TABLE 120. SHIRE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET
  • FIGURE 3. SEGMENTATION HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHEREDITARY ANGIOEDEMA THERAPEUTIC MARKET
  • FIGURE 11. HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 12. HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET FOR INTRAVENOUS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET FOR SUBCUTANEOUS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET FOR ORAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 16. HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET FOR SHORT TERM PROPHYLAXIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET FOR LONG TERM PROPHYLAXIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 21. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 22. COMPETITIVE DASHBOARD
  • FIGURE 23. COMPETITIVE HEATMAP: HEREDITARY ANGIOEDEMA THERAPEUTIC MARKET
  • FIGURE 24. TOP PLAYER POSITIONING, 2024
  • FIGURE 25. CSL BEHRING,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 26. CSL BEHRING,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 27. CSL BEHRING,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 28. TAKEDA PHARMACEUTICAL COMPANY LIMITED,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. TAKEDA PHARMACEUTICAL COMPANY LIMITED,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. TAKEDA PHARMACEUTICAL COMPANY LIMITED,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. TAKEDA PHARMACEUTICAL COMPANY,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. TAKEDA PHARMACEUTICAL COMPANY,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. TAKEDA PHARMACEUTICAL COMPANY,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. PHARMING HEALTHCARE, INC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. PHARMING HEALTHCARE, INC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. PHARMING HEALTHCARE, INC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. BIOCRYST PHARMACEUTICALS, INC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. BIOCRYST PHARMACEUTICALS, INC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. BIOCRYST PHARMACEUTICALS, INC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. ATTUNE PHARMACEUTICALS, INC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. ATTUNE PHARMACEUTICALS, INC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. ATTUNE PHARMACEUTICALS, INC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. IONIS PHARMACEUTICALS,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. IONIS PHARMACEUTICALS,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. IONIS PHARMACEUTICALS,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. KALVISTA PHARMACEUTICALS, INC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. KALVISTA PHARMACEUTICALS, INC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. KALVISTA PHARMACEUTICALS, INC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. ADVERUM BIOTECHNOLOGIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. ADVERUM BIOTECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. ADVERUM BIOTECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. SHIRE PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. SHIRE PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. SHIRE PLC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Hereditary Angioedema Therapeutic Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved